107754-56-3

Upstream product

• 70264-94-7 methyl 4-(bromomethyl)-3-methoxybenzoate 
• 94-52-0 5-nitrobenzimidazole 
• 107754-55-2 methyl 3-methoxy-4-<(6-nitrobenzimidazol-1-yl)methyl>benzoate 
• 107754-54-1 methyl 4-<(6-aminobenzimidazol-1-yl)methyl>-3-methoxybenzoate 
• 50715-28-1 cyclopentyl chloroformate 
• 107754-53-0 methyl 4-<<6-<<(cyclopentyloxy)carbonyl>amino>benzimidazol-1-yl>methyl>-3-methoxybenzoate 

Downstream Products

• 107786-78-7 N-<4-<<6-<<(cyclopentyloxy)carbonyl>amino>benzimidazol-1-yl>methyl>-3-methoxybenzoyl>benzenesulfonamide 

Relevant academic research and scientific papers

Synthesis and in vitro LTD4 antagonist activity of bicyclic and monocyclic cyclopentylurethane and cyclopentylacetamide N-arylsulfonyl amides

The dissociation constants (K(B)) at the LTD4 receptor on guinea pig trachea of a series of monocyclic and bicyclic cyclopentylurathane and cyclopentylacetamide N-arylsulfonyl amides have been measured. The K(B) was found to be remarkably toler

Heterocyclic amide derivatives and pharmaceutical use

The invention concerns novel, pharmaceutically useful, amide derivatives of certain benzoheterocyclylalkanoic acids (and related tetrazoles and acylsulphonamides) of the formula I and salts thereof, wherein the radicals R1, R2, L, X, Y, Z, A1, Q, A2 and M have the meanings set out in the specification. The invention also includes pharmaceutical compositions incorporating a formula I compound or a salt thereof, a process for the manufacture of the said compound, together with intermediates for use in the latter process. STR1